Delos Capital

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.

OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.

Imperative Care, Inc. is a medical technology company dedicated to enhancing acute stroke treatment. Founded in 2015 and based in Campbell, California, the company develops innovative solutions aimed at addressing critical needs in stroke care. Its primary offerings include the Large Distal Platform, a large diameter catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic strokes. Additionally, the ZOOM Aspiration System works in conjunction with the Large Distal Platform, providing a comprehensive solution for clot removal across various occlusion sizes, from the internal carotid artery to M2. By focusing on expediting and improving treatment effectiveness, Imperative Care aims to offer patients a greater chance for optimal recovery.

Phanes Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2016. It specializes in the discovery and development of therapeutics aimed at treating solid tumors and eye diseases. The company's portfolio includes a monoclonal antibody designed for solid tumors and various ophthalmic conditions such as age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, Phanes Therapeutics is developing a bispecific antibody targeting small cell lung cancer. With a focus on scientific innovation, the company strives to create advanced therapeutic options that enhance patient care and improve lives worldwide.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

Clover Biopharmaceuticals is a clinical-stage biotechnology company based in Chengdu, China, focused on discovering and developing innovative biologic therapies for cancer, autoimmune diseases, and infectious diseases. Founded in 2007, the company utilizes its proprietary Trimer-Tag technology platform to create novel biologics that target trimerization-dependent pathways. Clover also offers integrated biopharmaceutical drug manufacturing services and has in-house capabilities for cGMP biomanufacturing, which support the development of select biosimilars. Through its research and development efforts, Clover aims to bring transformative therapies to the market.

Rejoni, Inc. develops and commercializes medical devices that assist in gynecological surgical procedures. It focuses on preventing scar formation following intrauterine instrumented interventions. The company produces gynecological products using biomaterials. Rejoni, Inc. was founded in 2020 and is based in Bedford, Massachusetts.

Imperative Care, Inc. is a medical technology company dedicated to enhancing acute stroke treatment. Founded in 2015 and based in Campbell, California, the company develops innovative solutions aimed at addressing critical needs in stroke care. Its primary offerings include the Large Distal Platform, a large diameter catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic strokes. Additionally, the ZOOM Aspiration System works in conjunction with the Large Distal Platform, providing a comprehensive solution for clot removal across various occlusion sizes, from the internal carotid artery to M2. By focusing on expediting and improving treatment effectiveness, Imperative Care aims to offer patients a greater chance for optimal recovery.

Clover Biopharmaceuticals is a clinical-stage biotechnology company based in Chengdu, China, focused on discovering and developing innovative biologic therapies for cancer, autoimmune diseases, and infectious diseases. Founded in 2007, the company utilizes its proprietary Trimer-Tag technology platform to create novel biologics that target trimerization-dependent pathways. Clover also offers integrated biopharmaceutical drug manufacturing services and has in-house capabilities for cGMP biomanufacturing, which support the development of select biosimilars. Through its research and development efforts, Clover aims to bring transformative therapies to the market.

Curamir is a Woburn, MA-based biotechnology company launched and incubated by Delos Capital with an initial academic licensing from SUNY. Through its proprietary miRNA engineering platform and insights into cancer biology, Curamir develops miRNA-based cancer therapeutics with enhanced safety, potency and stability. Its novel approach addresses current challenges associated with both chemoresistance in cancer and effective systemic delivery of miRNA mimics.

OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.

Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

HOP Energy, LLC, a full-service energy company, provides residential and commercial energy services throughout the Northeast. Its services to residential customers include heating oils; propane fuel and tanks; selling and installing a range of heating and cooling equipment; 24 hour service; and comprehensive service contracts for heating, air conditioning, and other important equipment, such as water heaters and humidifiers.

US Fitness Products has been selling and servicing top brands of fitness and gym equipment for over 20 years. In addition to being North Carolina’s authorized dealer for Precor fitness equipment, they carry a wide selection of home and commercial grade fitness equipment from the best brands, well as accessories. And with a showroom in every location, you can try out your next fitness equipment purchase with the help of one of their highly trained staff members. Come see us today for your fitness equipment and gym equipment needs!

Sage Metals Ltd. is a manufacturer of specialty metal products serving the North American electrical, power utility, industrial, and drainage end markets. The Company was founded over 30 years ago.

Liposeuticals, Inc. develops and manufactures proprietary formulations of sterile injectable drugs. The company offers non-water-soluble drugs for anesthesiology, oncology and infectious diseases. Its products include Diprivan, Taxotere, Taxol, Vfend, Gemzar, Eloxatin, Platinol, Paraplatin, Emend tm., Prograf, and Alimta. Liposeuticals, Inc. was founded in 2012 and is headquartered in Monmouth Junction, New Jersey.

Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Allecra Therapeutics GmbH develops pharmaceuticals to treat gram-negative multi drug-resistant bacterial infections. The company was founded in 2013 and is based in Weil am Rhein, Germany.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, that focuses on developing innovative therapies for cancer treatment. The company's lead product candidate, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for mixed lineage leukemia and acute myeloid leukemia with specific mutations. The company also explores combinations of entinostat with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Another key asset is SNDX-6352, a monoclonal antibody being evaluated for chronic graft versus host disease and solid tumors. Syndax has established collaborations with major pharmaceutical companies and research institutions to enhance its clinical development efforts and expand its therapeutic pipeline.

Atia Vision, Inc. operates as a medical device company. It develops modular presbyopia correcting intraocular lens to address the needs in intraocular lens replacement market. Atia Vision, Inc. was incorporated in 2012 and is based in Campbell, California.

FCA, LLC has been a leader in the industrial packaging sector since its establishment in 1985, providing a diverse array of customized heavy-duty packaging solutions to prominent original equipment manufacturers across various industries, including aerospace, construction, and energy. The company specializes in designing and manufacturing a wide range of packaging products, such as wood, steel, corrugated, and hybrid solutions, which include engineered skids, crates, pallets, boxes, and collapsible packaging. These products are aimed at enhancing packaging protection and safeguarding valuable customer inventory. In addition to its core offerings, FCA provides value-added services that encompass design, testing, manufacturing, container management, tracking, recycling management, and repair or refurbishment. The company also emphasizes just-in-time delivery, ensuring clients receive cost-effective solutions that optimize their packaging needs and contribute to significant cost savings.